%A XIA Li, WANG Yue-ying %T Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy %0 Journal Article %D 2017 %J Journal of Shanghai Jiao Tong University (Medical Science) %R 10.3969/j.issn.1674-8115.2017.06.019 %P 822- %V 37 %N 6 %U {https://xuebao.shsmu.edu.cn/CN/abstract/article_11583.shtml} %8 2017-06-28 %X

 Chimeric antigen receptor T-cell (CAR-T) immunotherapy is a new type of immunotherapy, which has been developed rapidly in recent years. By using gene recombination and transfection techniques, CAR-modified effector T cells that specially recognize tumor-associated antigen was produced, which show better properties of targeting, killing activity and durability than conventional T cells. With the development of translational medicine research, CAR-T technology has experienced four generations of optimization and innovation, and presented a promising clinical efficacy in the treatment of various cancers, especially hematological malignancies. However, there are also potential risks with clinical use of this new technology, such as the off-target effect and cytokine storm. In this review, the progress, side effects, coping strategy, and development prospects of CAR-T in hematological malignancies immunotherapy were discussed.